Fate Therapeutics, Inc.
FATE
$1.08
$0.087.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.14M | 8.47M | 13.34M | 13.63M | 13.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.14M | 8.47M | 13.34M | 13.63M | 13.45M |
| Cost of Revenue | 75.93M | 84.75M | 86.16M | 89.16M | 88.43M |
| Gross Profit | -68.80M | -76.28M | -72.83M | -75.53M | -74.99M |
| SG&A Expenses | 67.59M | 77.75M | 83.56M | 90.64M | 92.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 167.13M | 186.11M | 199.09M | 209.17M | 210.05M |
| Operating Income | -159.99M | -177.64M | -185.75M | -195.54M | -196.60M |
| Income Before Tax | -156.09M | -171.52M | -175.88M | -186.26M | -178.23M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -156.09 | -171.52 | -175.88 | -186.26 | -178.23 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -156.09M | -171.52M | -175.88M | -186.26M | -178.23M |
| EBIT | -159.99M | -177.64M | -185.75M | -195.54M | -196.60M |
| EBITDA | -145.34M | -161.61M | -168.28M | -176.58M | -177.57M |
| EPS Basic | -1.32 | -1.45 | -1.49 | -1.65 | -1.65 |
| Normalized Basic EPS | -0.75 | -0.83 | -0.85 | -0.95 | -1.07 |
| EPS Diluted | -1.32 | -1.45 | -1.49 | -1.65 | -1.65 |
| Normalized Diluted EPS | -0.75 | -0.83 | -0.85 | -0.95 | -1.07 |
| Average Basic Shares Outstanding | 473.70M | 472.47M | 471.41M | 454.14M | 434.96M |
| Average Diluted Shares Outstanding | 473.70M | 472.47M | 471.41M | 454.14M | 434.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |